This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ7M0ZL_L.jpg
(Reuters) – The U.S. Food and Drug Administration’s independent experts on Wednesday narrowly voted against recommending the approval of Medtronic (NYSE:MDT)’s blood pressure treatment device, saying risks tied to using it do not outweigh the benefits.
The same panel on Tuesday voted in favor of rival ReCor’s device for use in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs.
